Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Incyte performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Net sales: $1.49 billion versus $1.29 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +40.5% change.
• Revenues- Product royalty revenues: $174.69 million versus the eight-analyst average estimate of $162.52 million. The reported number represents a year-over-year change of +15.6%.
• Net sales- Iclusig: $34.39 million versus $35.49 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +5.1% change.
• Net sales- Pemazyre: $23.42 million compared to the $22.42 million average estimate based on eight analysts. The reported number represents a change of +5.5% year over year.
• Net sales- Minjuvi/ Monjuvi: $53.69 million versus the eight-analyst average estimate of $50.59 million. The reported number represents a year-over-year change of +72.5%.
• Net sales- Opzelura: $449.74 million versus $277.8 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +173.4% change.
• Net sales- Jakafi: $816.66 million versus the eight-analyst average estimate of $797.99 million. The reported number represents a year-over-year change of +6.9%.
• Net sales- Niktimvo: $60.31 million versus the seven-analyst average estimate of $63.8 million. The reported number represents a year-over-year change of +66.8%.
• Net sales- Zynyz: $49.95 million compared to the $43.83 million average estimate based on seven analysts. The reported number represents a change of +459.9% year over year.
• Royalty revenues- Olumiant: $38.48 million versus the seven-analyst average estimate of $36.87 million. The reported number represents a year-over-year change of +14.9%.
• Royalty revenues- Tabrecta: $6.69 million versus $7.11 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +0.9% change.
• Royalty revenues- Jakavi: $124.19 million versus the seven-analyst average estimate of $116.95 million. The reported number represents a year-over-year change of +13.2%.

View all Key Company Metrics for Incyte here>>>

Shares of Incyte have returned +3.7% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research